{"ticker": {"uuid": "57b36846-e84d-4cdf-8a15-65e4e22e60f7", "symbol": "IMCR", "name": "Immunocore Holdings Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh", "summary": "This article provides financial information for Immunocore Holdings Plc, specifically its price to earnings forward ratio. The data is presented on the TradingView platform, with market data from ICE Data Services and reference data from FactSet. The company is listed on the Muni", "url": "https://www.tradingview.com/symbols/MUN-6YG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T22:12:08", "published_display": "13 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Immunocore stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdFFGcU81c2N6UTRjRFBjZGFhYVF6QUZwazRpZ29hb2QtZGJDVENsckdIalExa24xVG1fTjkzOVItVUY4eTZmZHVnMGJRZEROLVZhckN6d1NDMUw4SDN2al9lQXA4c2taTWVUN1FEdHVmZUpsMmJZdkJiSmk2cVctZ19CX05NT293VFd5X3ZqS0pfbVI5SkZpZ0VyZFNqeV9nOGpaX214Ym8teHJlenBLcHFpNEd3NjNHZm5KXw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T12:57:13+00:00", "published_display": "13 Jul 2026 12:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Immunocore Holdings (IMCR) Undervalued After Its Recent Share Price Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOS2VaVExVYlByV3RIdFhuMTFndFBoWThDRXNqZEZXaTRXbk90NTQ1emQ4ZnJnT2xJR1ZKdE9NRVl1bXV2czhUTGdmX1h6NEQxWG41c1Z2SUZJWmw3U1NnM2FaSkZ1bktMNkU5NFU5QVFzd2hPUGJVREp2Smcyd0YtQUx3b0tOekdvYTdKcWxBN1dxMHBvYld2OEZHdUc2bWRrTTBTdUM4aHBuQTVo?oc=5", "source_name": "Market source", "published_at": "2026-07-09T15:11:45+00:00", "published_display": "09 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings (IMCR) Rebounds On Pipeline Optimism, Is The Stock Still Cheap?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T01:45:42+00:00", "published_display": "09 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(IMCR) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily analyzes Immunocore Holdings Plc (NASDAQ: IMCR), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies resistance testing, suggesting a potential short setup with an exceptional 34.9:1 risk-reward ratio. ", "url": "https://news.stocktradersdaily.com/news_release/132/IMCR_Volatility_Zones_as_Tactical_Triggers_070826044402_1783500242.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T04:44:00", "published_display": "08 Jul 2026 04:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore stock holds its setup. Investors wait for the next verified trigger.", "summary": "Immunocore stock (IMCR) is currently trading without a new, live catalyst, with its story resting on its existing oncology platform centered around KIMMTRAK, a rare eye cancer medicine. The company, primarily listed in London with a US investor profile, relies on clinical, regula", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immunocore-stock-holds-its-setup-investors-wait-for-the-next-verified/69714876", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:13:35", "published_display": "07 Jul 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) Stock May Trade Above Fair Value On A 48% Slump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immunocore Holdings plc \u2013 NASDAQ:IMCR", "summary": "This article provides financial information for Immunocore Holdings plc (NASDAQ: IMCR), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were made. The content is primarily a data placehold", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:40:49", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immunocore Holdings plc \u2013 BOATS:IMCR", "summary": "This article provides financial information for Immunocore Holdings plc (IMCR) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-sales ratio. The content is presented within the TradingView platform context, indicating a data resour", "url": "https://www.tradingview.com/symbols/BOATS-IMCR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:12:41", "published_display": "30 Jun 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immunocore Holdings plc \u2013 BOATS:IMCR", "summary": "This article provides financial snapshot of Immunocore Holdings plc (IMCR) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-earnings ratio. It indicates the market was closed with no trades, offering period value, change, and perce", "url": "https://www.tradingview.com/symbols/BOATS-IMCR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:13:45", "published_display": "29 Jun 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immunocore Holdings plc \u2013 NASDAQ:IMCR", "summary": "This article focuses on the enterprise value to EBITDA forward metric for Immunocore Holdings plc (NASDAQ:IMCR). It appears to be a financial data point from TradingView, indicating a key valuation multiple for the biotechnology company. The content primarily lists navigational a", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T09:41:58", "published_display": "29 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Actuals & Estimates (NASDAQ:IMCR)", "summary": "This page on TradingView provides an overview of Immunocore Holdings plc (IMCR) on the Nasdaq Stock Market. It offers financial actuals and estimates for the company, allowing users to explore reported financial data and analyst estimates across various statements like income, ba", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:48", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (IMCR) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Immunocore Holdings Plc (NASDAQ: IMCR), highlighting a positive near-term sentiment with a mid-channel oscillation pattern and an exceptional 39.0:1 risk-reward setup. It outlines three institutional trading strategies\u2014Position Tr", "url": "https://news.stocktradersdaily.com/news_release/139/Price-Driven_Insight_from_IMCR_for_Rule-Based_Strategy_062726033601_1782545761.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T03:39:48", "published_display": "27 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Immunocore Holdings plc (IMCR) for 2027 based on analyst ratings. Thirteen analysts have offered 1-year price forecasts, resulting in an average price target of 63.52, with specific maximum and minimum estimates not provided. T", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:10:24", "published_display": "27 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbExiV1Vrei1IdUhlVmNic1JkTEdSdDlpRzRFOUZfVUFjcl92SlpPQU11RjVqYTloVUZMazJJeS1ZdHZhMFZ1a0tuZG1lb2ZoNmNsY3ZBMXJhalZYQ0toYWptTDZ0VGxfcEFOX2tjSi1IUmIyR2t6RXlFTTRDMXBnck52WFF6ZktVNm15aWNNX19qNlI4ZFdJanhLYUhyMlJhVk1GenJPTFRNZzAwZ2hLZmsxelhEck0x?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Immunocore (IMCR) Melanoma Data Highlighting Brenetafusp\u2019s Potential In PD\u20111\u2011Resistant Disease", "summary": "Immunocore recently released encouraging Phase 1/2 data for its brenetafusp therapy in advanced melanoma, particularly for PD-1-resistant patients, which could significantly impact the company's investment narrative. The data strengthens confidence in the ongoing Phase 3 PRISM-ME", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/how-investors-may-respond-to-immunocore-imcr-melanoma-data-h/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-23T00:09:36", "published_display": "23 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?", "summary": "Immunocore Holdings plc (NASDAQ: IMCR) is highlighted as a promising small-cap stock for long-term investment, with recent positive Phase 1/2 trial results for its brenetafusp treatment for advanced melanoma. The company, a commercial-stage biotechnology firm, focuses on developi", "url": "https://www.insidermonkey.com/blog/is-immunocore-holdings-imcr-one-of-the-best-small-cap-stocks-to-buy-for-the-long-term-1786163/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-22T08:10:00", "published_display": "22 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings (IMCR) Stock Could Be 57% Below Fair Value After Recent Weakness", "summary": "Immunocore Holdings (IMCR) has experienced a recent stock pullback but is considered by one narrative to be 57% undervalued, with a fair value of $66.57 compared to its current price of $28.60. The valuation gap is attributed to the growing market for cancer and rare disease ther", "url": "https://finance.yahoo.com/markets/stocks/articles/immunocore-holdings-imcr-stock-could-161344320.html", "source_name": "Market source", "published_at": "2026-06-19T16:39:21", "published_display": "19 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR SEC Filings - Immunocore Holdings Plc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Immunocore Holdings Plc (IMCR) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details recent filings such as a 10-Q report from August 7, 2025, and a Schedule 13G/A filing from Augus", "url": "https://www.stocktitan.net/sec-filings/IMCR/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:13:40", "published_display": "18 Jun 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immunocore Holdings PLC's (IMCR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock performance dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:41:04", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Immunocore Holdings PLC (IMCR), detailing its regional revenue contributions. For 2023, the United States accounted for 64.25% of revenue, Europe for 32.85%, and international markets for 2.90%. The company has not yet disclosed detai", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:41:04", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Immunocore Holdings PLC (IMCR) currently has an earnings forecast score of 8.12, ranking it 53rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $70.00, with a high of $100.00 and a low of $36.00, indicating a significant upside potential ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:51", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Immunocore Holdings PLC (IMCR), noting its current valuation score of 7.88, ranking 117 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is -51.99, which is below its recent high and above its recent low. Key P/B, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:21", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is it a Good Idea to Invest in Immunocore Stock Right Now?", "summary": "Immunocore (IMCR) is experiencing strong sales growth for its primary drug, Kimmtrak, which generated $400 million in 2025 and $106.7 million in Q1 2026. The company is actively pursuing label expansion for Kimmtrak and developing other pipeline candidates, including brenetafusp ", "url": "https://sg.finance.yahoo.com/news/good-idea-invest-immunocore-stock-135900829.html", "source_name": "Market source", "published_at": "2026-06-17T09:59:00", "published_display": "17 Jun 2026 09:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Institutional Confidence", "summary": "Immunocore Holdings PLC (IMCR) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding stands at 97.50%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder with ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T19:40:40", "published_display": "16 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price Small-Cap Stock Fund, Inc.'s Immunocore Holdings PLC(IMCR) Holding History", "summary": "This article details T. Rowe Price Small-Cap Stock Fund, Inc.'s investment history in Immunocore Holdings PLC (IMCR). As of March 31, 2026, the fund held 465,030 shares of IMCR, valued at $14.02 million, representing 0.18% of its portfolio. Since initial trading in Q4 2023, the f", "url": "https://www.gurufocus.com/guru-portfolio/T.%20Rowe%20Price%20Small-Cap%20Stock%20Fund,%20Inc./IMCR", "source_name": "GuruFocus", "published_at": "2026-06-16T19:40:39", "published_display": "16 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(IMCR) Price Dynamics and Execution-Aware Positioning", "summary": "Immunocore Holdings Plc (NASDAQ: IMCR) is exhibiting a mid-channel oscillation pattern with a positive near-term sentiment that may shift. AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profile", "url": "https://news.stocktradersdaily.com/news_release/141/IMCR_Price_Dynamics_and_Execution-Aware_Positioning_061626022402_1781591042.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T02:08:59", "published_display": "16 Jun 2026 02:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(IMCR) as a Liquidity Pulse for Institutional Tactics", "summary": "Immunocore Holdings Plc (NASDAQ: IMCR) shows stable neutral readings in shorter time horizons, potentially signaling an easing of a long-term weak bias. The AI analysis identifies a mid-channel oscillation pattern and presents an exceptional 41.6:1 risk-reward setup, targeting a ", "url": "https://news.stocktradersdaily.com/news_release/150/IMCR_as_a_Liquidity_Pulse_for_Institutional_Tactics_060526125402_1780635242.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-05T00:54:00", "published_display": "05 Jun 2026 00:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100", "summary": "H.C. Wainwright has reiterated its Buy rating for Immunocore (IMCR.US) and maintained a target price of $100. This continued positive outlook suggests the firm sees strong potential in the company's financial or operational performance.", "url": "https://www.moomoo.com/news/post/71023966/hc-wainwright-maintains-immunocore-imcrus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-04T02:39:44", "published_display": "04 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Reports 14.3-Month Survival in Phase 1/2 Trial of Advanced Melanoma Drug Candidate", "summary": "Immunocore Holdings, a late-stage biotechnology company, announced updated data from its Phase 1/2 clinical trial of IMC-F106C (brentuximab vedotin) as a treatment for advanced cutaneous melanoma. The data indicated a median overall survival of 14.3 months, with a 6-month overall", "url": "https://www.moomoo.com/news/post/70852646/immunocore-reports-14-3-month-survival-in-phase-1-2", "source_name": "Moomoo", "published_at": "2026-06-02T09:09:15", "published_display": "02 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides an in-depth financial analysis of Immunocore Holdings PLC (IMCR), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is product sales, accounting for 96.6% of total sales, alongside", "url": "https://intellectia.ai/en/stock/IMCR/financials", "source_name": "Intellectia AI", "published_at": "2026-06-02T04:09:15", "published_display": "02 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Immunocore Holdings (IMCR) Valuation After New Brenetafusp Data At The 2026 ASCO Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNd25BSGlpMU9razdLcHRyTXk2Mld3aUhVT0lpLWRKZ2VHeEp1RGZHenEwdlo2ZlpucHFaUmZEeTVPei03bjNMVVZtNVE5dTdXbEpza0xleDJReFdKMmVBMHlvMHZTOFFXOElWc0VsaEVZQk9QZVE4cFc0YUIzNVJDRGZFX0tnYkM1NVhwalBIM0NrRENwNEVzLUlrVDhKeEwtSnVVTk1nZURvR1lNR0dmbXhvVQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore trial: brenetafusp 14.3-month survival in melanoma", "summary": "Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated, HLA-A*02:01-positive advanced melanoma patients, showing a median overall survival of 14.3 months and a 6-month survival rate of 87%. The data, presented at ASCO 2026, also indicated a 52% disease ", "url": "https://www.stocktitan.net/news/IMCR/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-d8okomxtu70z.html", "source_name": "Stock Titan", "published_at": "2026-06-01T00:40:19", "published_display": "01 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma", "summary": "Immunocore Holdings plc announced updated Phase 1/2 clinical trial data for brenetafusp in patients with advanced melanoma. The monotherapy showed an 87% 6-month overall survival rate and a 52% disease control rate in heavily pretreated patients, supporting the 160 mcg dose for t", "url": "https://investingnews.com/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma/", "source_name": "Investing News Network", "published_at": "2026-05-31T14:10:22", "published_display": "31 May 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) director awarded 27,492 share options", "summary": "Immunocore Holdings plc director Roy Steven Herbst was granted 27,492 share options with an exercise price of $28.52 per share, set to expire on May 26, 2036. These options will vest by May 27, 2027, or the day before the company's next annual general meeting, contingent on his c", "url": "https://www.stocktitan.net/sec-filings/IMCR/form-4-immunocore-holdings-plc-insider-trading-activity-9d0a80b1be48.html", "source_name": "Stock Titan", "published_at": "2026-05-31T03:09:42", "published_display": "31 May 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPeElRWnBvREo1RGd4ejEyRzJ1dUI3ZVdsR2N5cVVmSmVMTl92Q2RsTEdCTkF6T0JkWjNndFhDSHdpMWdqeVRtMDYtN0JKQk1PdWRHXzhJemZxUzk0MmlKOUtDU1ZYcUU2VjllVkRMdHlnUlVhVEliWUJGdzFLZ0F1aGw1VHZpRlBMMU13UF9mMXItX1k1Y2xOQ3pYajF1Q29KalZwdg?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQOUQwa1Ixc1Awc1pDLXFWa29oNWUySG8tNmo1QnlyVnBLTXc3R0ZUR2c4aUdaR1JxTGFZa2FsWlMyS1JiQkpZLUpmOWdWSFNrQ2RVMnUwN1NDZ1BYd0tTemtOTFNZR0Z5WG1rZUEzbk02cnNxNVJxc0g5blg1Q0hGYl9XOGlFSFRrWXdYWHNlc1pEZkRVSk1nSzJFWE9BRmoxaUd0Zg?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) Returns To Quarterly Profit And Tests Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And Efficiency", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQcm9mZ1FUMVdwOG90cVJfUkEzcEtuXzh5aFBnaDJBVWRNT2JCdF8yY3c0emJCNl9rREdJdkpEVjNuYjJOYjAtYjAyY04zZ0p5cjNORllMN2IzUnpFdVc5aEMxZTE4NW85RTR5dDdKUnhVMnJOZE8zb3d4N3JvUmxHc3UtaTlHbEh5aDE3Y0ZNZ1YxdHlQVWVv?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR Financials: Income Statement, Balance Sheet & Cash Flow | Immunocore Holdings Plc", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5rNzVOYkFqLXpkM2l6QzdoT1k0OVhUeGdONlJ0ZE5qN1hRbEJpMEtsSTY3RmZJbHE5TEtvaUJZWlNQUTdoTElWa0x6RmxlMVhnZV93Y19B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunocore executives join Needham virtual healthcare event April 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVzdpZmZ4c282RWR6dTFRMzdDZFI3T2JieG1yNWhPMm1mVEZPSXNINmhaWndKMWtzOWVaQUNBa1VoTzNSaVNzV3UwTVdQSVpsVVpJWk51SE8tQ3VOSDl4dG5JckF6anEtR0NOV1BkZEpWUlBkVGk3dWpFOEMzOUhHQU9ZbHcxckZkQ2YxNmJCaWtXVDBFRkZjZE41ZlkxTHdrRl82VkVBdmRuMVhXZm9mNjJpUmNnWXF3cVdtR1AxZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUF92R3U4LTZRTHUxcGg3aG9CMjRDa1VoRWxXcDJtTGlzRUNWUzB6cUg2MnZiMjI4LTA4UkxPc19HS3FWSnVfc3kzR0hQMTJuaHRaLVhMSTFEOW9aZ0pvbWxRMHFkX1E4VkdOT1FDQXRsMnZMR2dnMEE2WWNTVmdCU3JzNkVUVS1pdU5SWVV1MWIzd05tcW1XQW0wak5KNWpmMURGeG9GbFI?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLXBjRzBzU1dCUDRSTFIxWHRaZU1VV2syVzlvNE5qMFdWRm9UZmJXWFBOa0NQQ0NBcTJRRDgtOEJ0cW0zanZpM0dSMHpXTUV4cUlNcXVTcUxEeUd4T2RIa0VKOXZiWTh6dXItU09SbmlQaDV6Z1FSWkg1RWp5UjFqb01uOVQ4dzNoRzJxUlNTSEtrdkFBeGtnZTVaYlpyZlhpZ1lvWUNHTmh6MW9IWHc?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm Immunocore lines up March investor talks in Miami and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQc1NKQzZVTk9zVmotOEpsaC1sd3pDV05aaU9RUFBHQ2l4Tk5WV05DWWJqX0I4S2VBRXlhanZ1YU51LTFmM0w4dkVNRlQ5WjR1VEJELVkxbThUSk1mNXI3OVdhREt0MFBHVXhEVDlIWW9zdGNLMlgwM1VHZ085NTVsTVU3Y0d1RExlNW1id3JKREdJalFkYTIzdUdOWk9hZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Narrative Around Immunocore (IMCR) Is Shifting With New Analyst Targets And 2026 Hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPcE1DenZjYkpoNUxiZmlhUmQwNE5nRHVWWHJkSVNvcDZKZ1kzRHlBZ1dya1JRdXVsUkpCdE82Nks2dWY2eGxKOWFmZGlHeWE2NEtrOEc4ZlNtcFZhX3pnNDVBNEttRkZ5cERhUFV4cEpTb1dVZmF2TW5aeENjeXNvN3piTGYwSm5qYkE?oc=5", "source_name": "Market source", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Reshapes R&D Leadership As Shares Trade Below Analyst Targets", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh", "summary": "This article provides financial information for Immunocore Holdings Plc, specifically its price to earnings forward ratio. The data is presented on the TradingView platform, with market data from ICE Data Services and reference data from FactSet. The company is listed on the Muni", "url": "https://www.tradingview.com/symbols/MUN-6YG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T22:12:08", "published_display": "13 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on Immunocore stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQdFFGcU81c2N6UTRjRFBjZGFhYVF6QUZwazRpZ29hb2QtZGJDVENsckdIalExa24xVG1fTjkzOVItVUY4eTZmZHVnMGJRZEROLVZhckN6d1NDMUw4SDN2al9lQXA4c2taTWVUN1FEdHVmZUpsMmJZdkJiSmk2cVctZ19CX05NT293VFd5X3ZqS0pfbVI5SkZpZ0VyZFNqeV9nOGpaX214Ym8teHJlenBLcHFpNEd3NjNHZm5KXw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T12:57:13+00:00", "published_display": "13 Jul 2026 12:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunocore Holdings (IMCR) Undervalued After Its Recent Share Price Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOS2VaVExVYlByV3RIdFhuMTFndFBoWThDRXNqZEZXaTRXbk90NTQ1emQ4ZnJnT2xJR1ZKdE9NRVl1bXV2czhUTGdmX1h6NEQxWG41c1Z2SUZJWmw3U1NnM2FaSkZ1bktMNkU5NFU5QVFzd2hPUGJVREp2Smcyd0YtQUx3b0tOekdvYTdKcWxBN1dxMHBvYld2OEZHdUc2bWRrTTBTdUM4aHBuQTVo?oc=5", "source_name": "Market source", "published_at": "2026-07-09T15:11:45+00:00", "published_display": "09 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings (IMCR) Rebounds On Pipeline Optimism, Is The Stock Still Cheap?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T01:45:42+00:00", "published_display": "09 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(IMCR) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily analyzes Immunocore Holdings Plc (NASDAQ: IMCR), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies resistance testing, suggesting a potential short setup with an exceptional 34.9:1 risk-reward ratio. ", "url": "https://news.stocktradersdaily.com/news_release/132/IMCR_Volatility_Zones_as_Tactical_Triggers_070826044402_1783500242.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T04:44:00", "published_display": "08 Jul 2026 04:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore stock holds its setup. Investors wait for the next verified trigger.", "summary": "Immunocore stock (IMCR) is currently trading without a new, live catalyst, with its story resting on its existing oncology platform centered around KIMMTRAK, a rare eye cancer medicine. The company, primarily listed in London with a US investor profile, relies on clinical, regula", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/immunocore-stock-holds-its-setup-investors-wait-for-the-next-verified/69714876", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T14:13:35", "published_display": "07 Jul 2026 14:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) Stock May Trade Above Fair Value On A 48% Slump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immunocore Holdings plc \u2013 NASDAQ:IMCR", "summary": "This article provides financial information for Immunocore Holdings plc (NASDAQ: IMCR), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were made. The content is primarily a data placehold", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:40:49", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immunocore Holdings plc \u2013 BOATS:IMCR", "summary": "This article provides financial information for Immunocore Holdings plc (IMCR) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-sales ratio. The content is presented within the TradingView platform context, indicating a data resour", "url": "https://www.tradingview.com/symbols/BOATS-IMCR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:12:41", "published_display": "30 Jun 2026 05:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immunocore Holdings plc \u2013 BOATS:IMCR", "summary": "This article provides financial snapshot of Immunocore Holdings plc (IMCR) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-earnings ratio. It indicates the market was closed with no trades, offering period value, change, and perce", "url": "https://www.tradingview.com/symbols/BOATS-IMCR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:13:45", "published_display": "29 Jun 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immunocore Holdings plc \u2013 NASDAQ:IMCR", "summary": "This article focuses on the enterprise value to EBITDA forward metric for Immunocore Holdings plc (NASDAQ:IMCR). It appears to be a financial data point from TradingView, indicating a key valuation multiple for the biotechnology company. The content primarily lists navigational a", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T09:41:58", "published_display": "29 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Actuals & Estimates (NASDAQ:IMCR)", "summary": "This page on TradingView provides an overview of Immunocore Holdings plc (IMCR) on the Nasdaq Stock Market. It offers financial actuals and estimates for the company, allowing users to explore reported financial data and analyst estimates across various statements like income, ba", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:48", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (IMCR) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Immunocore Holdings Plc (NASDAQ: IMCR), highlighting a positive near-term sentiment with a mid-channel oscillation pattern and an exceptional 39.0:1 risk-reward setup. It outlines three institutional trading strategies\u2014Position Tr", "url": "https://news.stocktradersdaily.com/news_release/139/Price-Driven_Insight_from_IMCR_for_Rule-Based_Strategy_062726033601_1782545761.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T03:39:48", "published_display": "27 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Immunocore Holdings plc (IMCR) for 2027 based on analyst ratings. Thirteen analysts have offered 1-year price forecasts, resulting in an average price target of 63.52, with specific maximum and minimum estimates not provided. T", "url": "https://www.tradingview.com/symbols/NASDAQ-IMCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:10:24", "published_display": "27 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbExiV1Vrei1IdUhlVmNic1JkTEdSdDlpRzRFOUZfVUFjcl92SlpPQU11RjVqYTloVUZMazJJeS1ZdHZhMFZ1a0tuZG1lb2ZoNmNsY3ZBMXJhalZYQ0toYWptTDZ0VGxfcEFOX2tjSi1IUmIyR2t6RXlFTTRDMXBnck52WFF6ZktVNm15aWNNX19qNlI4ZFdJanhLYUhyMlJhVk1GenJPTFRNZzAwZ2hLZmsxelhEck0x?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Immunocore (IMCR) Melanoma Data Highlighting Brenetafusp\u2019s Potential In PD\u20111\u2011Resistant Disease", "summary": "Immunocore recently released encouraging Phase 1/2 data for its brenetafusp therapy in advanced melanoma, particularly for PD-1-resistant patients, which could significantly impact the company's investment narrative. The data strengthens confidence in the ongoing Phase 3 PRISM-ME", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/how-investors-may-respond-to-immunocore-imcr-melanoma-data-h/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-23T00:09:36", "published_display": "23 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?", "summary": "Immunocore Holdings plc (NASDAQ: IMCR) is highlighted as a promising small-cap stock for long-term investment, with recent positive Phase 1/2 trial results for its brenetafusp treatment for advanced melanoma. The company, a commercial-stage biotechnology firm, focuses on developi", "url": "https://www.insidermonkey.com/blog/is-immunocore-holdings-imcr-one-of-the-best-small-cap-stocks-to-buy-for-the-long-term-1786163/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-22T08:10:00", "published_display": "22 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings (IMCR) Stock Could Be 57% Below Fair Value After Recent Weakness", "summary": "Immunocore Holdings (IMCR) has experienced a recent stock pullback but is considered by one narrative to be 57% undervalued, with a fair value of $66.57 compared to its current price of $28.60. The valuation gap is attributed to the growing market for cancer and rare disease ther", "url": "https://finance.yahoo.com/markets/stocks/articles/immunocore-holdings-imcr-stock-could-161344320.html", "source_name": "Market source", "published_at": "2026-06-19T16:39:21", "published_display": "19 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR SEC Filings - Immunocore Holdings Plc 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Immunocore Holdings Plc (IMCR) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details recent filings such as a 10-Q report from August 7, 2025, and a Schedule 13G/A filing from Augus", "url": "https://www.stocktitan.net/sec-filings/IMCR/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:13:40", "published_display": "18 Jun 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immunocore Holdings PLC's (IMCR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock performance dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:41:04", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Immunocore Holdings PLC (IMCR), detailing its regional revenue contributions. For 2023, the United States accounted for 64.25% of revenue, Europe for 32.85%, and international markets for 2.90%. The company has not yet disclosed detai", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:41:04", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Immunocore Holdings PLC (IMCR) currently has an earnings forecast score of 8.12, ranking it 53rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $70.00, with a high of $100.00 and a low of $36.00, indicating a significant upside potential ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:51", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Immunocore Holdings PLC (IMCR), noting its current valuation score of 7.88, ranking 117 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is -51.99, which is below its recent high and above its recent low. Key P/B, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:21", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is it a Good Idea to Invest in Immunocore Stock Right Now?", "summary": "Immunocore (IMCR) is experiencing strong sales growth for its primary drug, Kimmtrak, which generated $400 million in 2025 and $106.7 million in Q1 2026. The company is actively pursuing label expansion for Kimmtrak and developing other pipeline candidates, including brenetafusp ", "url": "https://sg.finance.yahoo.com/news/good-idea-invest-immunocore-stock-135900829.html", "source_name": "Market source", "published_at": "2026-06-17T09:59:00", "published_display": "17 Jun 2026 09:59", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Holdings PLC (IMCR) Institutional Confidence", "summary": "Immunocore Holdings PLC (IMCR) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding stands at 97.50%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder with ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-imcr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T19:40:40", "published_display": "16 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price Small-Cap Stock Fund, Inc.'s Immunocore Holdings PLC(IMCR) Holding History", "summary": "This article details T. Rowe Price Small-Cap Stock Fund, Inc.'s investment history in Immunocore Holdings PLC (IMCR). As of March 31, 2026, the fund held 465,030 shares of IMCR, valued at $14.02 million, representing 0.18% of its portfolio. Since initial trading in Q4 2023, the f", "url": "https://www.gurufocus.com/guru-portfolio/T.%20Rowe%20Price%20Small-Cap%20Stock%20Fund,%20Inc./IMCR", "source_name": "GuruFocus", "published_at": "2026-06-16T19:40:39", "published_display": "16 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(IMCR) Price Dynamics and Execution-Aware Positioning", "summary": "Immunocore Holdings Plc (NASDAQ: IMCR) is exhibiting a mid-channel oscillation pattern with a positive near-term sentiment that may shift. AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profile", "url": "https://news.stocktradersdaily.com/news_release/141/IMCR_Price_Dynamics_and_Execution-Aware_Positioning_061626022402_1781591042.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T02:08:59", "published_display": "16 Jun 2026 02:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(IMCR) as a Liquidity Pulse for Institutional Tactics", "summary": "Immunocore Holdings Plc (NASDAQ: IMCR) shows stable neutral readings in shorter time horizons, potentially signaling an easing of a long-term weak bias. The AI analysis identifies a mid-channel oscillation pattern and presents an exceptional 41.6:1 risk-reward setup, targeting a ", "url": "https://news.stocktradersdaily.com/news_release/150/IMCR_as_a_Liquidity_Pulse_for_Institutional_Tactics_060526125402_1780635242.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-05T00:54:00", "published_display": "05 Jun 2026 00:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100", "summary": "H.C. Wainwright has reiterated its Buy rating for Immunocore (IMCR.US) and maintained a target price of $100. This continued positive outlook suggests the firm sees strong potential in the company's financial or operational performance.", "url": "https://www.moomoo.com/news/post/71023966/hc-wainwright-maintains-immunocore-imcrus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-04T02:39:44", "published_display": "04 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Reports 14.3-Month Survival in Phase 1/2 Trial of Advanced Melanoma Drug Candidate", "summary": "Immunocore Holdings, a late-stage biotechnology company, announced updated data from its Phase 1/2 clinical trial of IMC-F106C (brentuximab vedotin) as a treatment for advanced cutaneous melanoma. The data indicated a median overall survival of 14.3 months, with a 6-month overall", "url": "https://www.moomoo.com/news/post/70852646/immunocore-reports-14-3-month-survival-in-phase-1-2", "source_name": "Moomoo", "published_at": "2026-06-02T09:09:15", "published_display": "02 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides an in-depth financial analysis of Immunocore Holdings PLC (IMCR), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is product sales, accounting for 96.6% of total sales, alongside", "url": "https://intellectia.ai/en/stock/IMCR/financials", "source_name": "Intellectia AI", "published_at": "2026-06-02T04:09:15", "published_display": "02 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Immunocore Holdings (IMCR) Valuation After New Brenetafusp Data At The 2026 ASCO Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNd25BSGlpMU9razdLcHRyTXk2Mld3aUhVT0lpLWRKZ2VHeEp1RGZHenEwdlo2ZlpucHFaUmZEeTVPei03bjNMVVZtNVE5dTdXbEpza0xleDJReFdKMmVBMHlvMHZTOFFXOElWc0VsaEVZQk9QZVE4cFc0YUIzNVJDRGZFX0tnYkM1NVhwalBIM0NrRENwNEVzLUlrVDhKeEwtSnVVTk1nZURvR1lNR0dmbXhvVQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore trial: brenetafusp 14.3-month survival in melanoma", "summary": "Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated, HLA-A*02:01-positive advanced melanoma patients, showing a median overall survival of 14.3 months and a 6-month survival rate of 87%. The data, presented at ASCO 2026, also indicated a 52% disease ", "url": "https://www.stocktitan.net/news/IMCR/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-d8okomxtu70z.html", "source_name": "Stock Titan", "published_at": "2026-06-01T00:40:19", "published_display": "01 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma", "summary": "Immunocore Holdings plc announced updated Phase 1/2 clinical trial data for brenetafusp in patients with advanced melanoma. The monotherapy showed an 87% 6-month overall survival rate and a 52% disease control rate in heavily pretreated patients, supporting the 160 mcg dose for t", "url": "https://investingnews.com/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma/", "source_name": "Investing News Network", "published_at": "2026-05-31T14:10:22", "published_display": "31 May 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) director awarded 27,492 share options", "summary": "Immunocore Holdings plc director Roy Steven Herbst was granted 27,492 share options with an exercise price of $28.52 per share, set to expire on May 26, 2036. These options will vest by May 27, 2027, or the day before the company's next annual general meeting, contingent on his c", "url": "https://www.stocktitan.net/sec-filings/IMCR/form-4-immunocore-holdings-plc-insider-trading-activity-9d0a80b1be48.html", "source_name": "Stock Titan", "published_at": "2026-05-31T03:09:42", "published_display": "31 May 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPeElRWnBvREo1RGd4ejEyRzJ1dUI3ZVdsR2N5cVVmSmVMTl92Q2RsTEdCTkF6T0JkWjNndFhDSHdpMWdqeVRtMDYtN0JKQk1PdWRHXzhJemZxUzk0MmlKOUtDU1ZYcUU2VjllVkRMdHlnUlVhVEliWUJGdzFLZ0F1aGw1VHZpRlBMMU13UF9mMXItX1k1Y2xOQ3pYajF1Q29KalZwdg?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQOUQwa1Ixc1Awc1pDLXFWa29oNWUySG8tNmo1QnlyVnBLTXc3R0ZUR2c4aUdaR1JxTGFZa2FsWlMyS1JiQkpZLUpmOWdWSFNrQ2RVMnUwN1NDZ1BYd0tTemtOTFNZR0Z5WG1rZUEzbk02cnNxNVJxc0g5blg1Q0hGYl9XOGlFSFRrWXdYWHNlc1pEZkRVSk1nSzJFWE9BRmoxaUd0Zg?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) Returns To Quarterly Profit And Tests Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And Efficiency", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQcm9mZ1FUMVdwOG90cVJfUkEzcEtuXzh5aFBnaDJBVWRNT2JCdF8yY3c0emJCNl9rREdJdkpEVjNuYjJOYjAtYjAyY04zZ0p5cjNORllMN2IzUnpFdVc5aEMxZTE4NW85RTR5dDdKUnhVMnJOZE8zb3d4N3JvUmxHc3UtaTlHbEh5aDE3Y0ZNZ1YxdHlQVWVv?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMCR Financials: Income Statement, Balance Sheet & Cash Flow | Immunocore Holdings Plc", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5rNzVOYkFqLXpkM2l6QzdoT1k0OVhUeGdONlJ0ZE5qN1hRbEJpMEtsSTY3RmZJbHE5TEtvaUJZWlNQUTdoTElWa0x6RmxlMVhnZV93Y19B?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore executives join Needham virtual healthcare event April 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVzdpZmZ4c282RWR6dTFRMzdDZFI3T2JieG1yNWhPMm1mVEZPSXNINmhaWndKMWtzOWVaQUNBa1VoTzNSaVNzV3UwTVdQSVpsVVpJWk51SE8tQ3VOSDl4dG5JckF6anEtR0NOV1BkZEpWUlBkVGk3dWpFOEMzOUhHQU9ZbHcxckZkQ2YxNmJCaWtXVDBFRkZjZE41ZlkxTHdrRl82VkVBdmRuMVhXZm9mNjJpUmNnWXF3cVdtR1AxZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUF92R3U4LTZRTHUxcGg3aG9CMjRDa1VoRWxXcDJtTGlzRUNWUzB6cUg2MnZiMjI4LTA4UkxPc19HS3FWSnVfc3kzR0hQMTJuaHRaLVhMSTFEOW9aZ0pvbWxRMHFkX1E4VkdOT1FDQXRsMnZMR2dnMEE2WWNTVmdCU3JzNkVUVS1pdU5SWVV1MWIzd05tcW1XQW0wak5KNWpmMURGeG9GbFI?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLXBjRzBzU1dCUDRSTFIxWHRaZU1VV2syVzlvNE5qMFdWRm9UZmJXWFBOa0NQQ0NBcTJRRDgtOEJ0cW0zanZpM0dSMHpXTUV4cUlNcXVTcUxEeUd4T2RIa0VKOXZiWTh6dXItU09SbmlQaDV6Z1FSWkg1RWp5UjFqb01uOVQ4dzNoRzJxUlNTSEtrdkFBeGtnZTVaYlpyZlhpZ1lvWUNHTmh6MW9IWHc?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm Immunocore lines up March investor talks in Miami and more", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQc1NKQzZVTk9zVmotOEpsaC1sd3pDV05aaU9RUFBHQ2l4Tk5WV05DWWJqX0I4S2VBRXlhanZ1YU51LTFmM0w4dkVNRlQ5WjR1VEJELVkxbThUSk1mNXI3OVdhREt0MFBHVXhEVDlIWW9zdGNLMlgwM1VHZ085NTVsTVU3Y0d1RExlNW1id3JKREdJalFkYTIzdUdOWk9hZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Narrative Around Immunocore (IMCR) Is Shifting With New Analyst Targets And 2026 Hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPcE1DenZjYkpoNUxiZmlhUmQwNE5nRHVWWHJkSVNvcDZKZ1kzRHlBZ1dya1JRdXVsUkpCdE82Nks2dWY2eGxKOWFmZGlHeWE2NEtrOEc4ZlNtcFZhX3pnNDVBNEttRkZ5cERhUFV4cEpTb1dVZmF2TW5aeENjeXNvN3piTGYwSm5qYkE?oc=5", "source_name": "Market source", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunocore Reshapes R&D Leadership As Shares Trade Below Analyst Targets", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 54, "sentiment_summary": {"positive": 16, "negative": 2, "neutral": 36, "score": 56, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.0, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 31.95, "latest_week": "2026-07-10", "one_week_move": -1.7, "four_week_move": 10.3, "twelve_week_move": 1.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.949507, "market_dynamics_buy_signal": false, "relative_strength": -16.879832, "fair_value_gap": -21.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.9769, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.7% over one week, +10.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "Stock Traders Daily", "count": 4}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 7}, {"label": "Balance sheet", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.7% over one week, +10.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh"}], "updated_at": "2026-07-16T00:39:17.993322+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}